Background: There is an amenable need for clinically applicable biomarkers in patients with SARS-CoV-2 infection. Red Cell Distribution Width (RDW) has been recently suggested as a prognostic biomarker for COVID-19. Methods: This was an observational study enrolling patients between February 26 and May 15 2020. We aimed to validate the association of the previously published RDW threshold of 14.5% with markers of disease progression and mortality. Results: A total number of 193 hospitalized patients with COVID-19 were enrolled and analyzed. Median age was 61 years (95% CI: 58-64). Patients with baseline RDW ≥14.5% (n = 41, 19.2%) presented with more progressive disease compared to patients with baseline RDW <14.5% (n = 156, 80.8%) as indicated by significant differences in maximum FiO2% during hospitalization (median: 100, 95% CI: 45.2-100, vs. 35, 95% CI: 31-40, p = 0.0001, respectively). Values of RDW ≥14.5% were also strongly associated with increased risk of mortality (HR: 4.1, 95% CI: 0.88-19.23), (p = 0.02). Conclusion: Our study provides evidence to support reproducibility and validity of a specified cut-off threshold of RDW as biomarker of disease severity and mortality in patients with COVID-19.
Background: There is an amenable need for clinically applicable biomarkers in patients with SARS-CoV-2 infection. Red Cell Distribution Width (RDW) has been recently suggested as a prognostic biomarker for COVID-19. Methods: This was an observational study enrolling patients between February 26 and May 15 2020. We aimed to validate the association of the previously published RDW threshold of 14.5% with markers of disease progression and mortality. Results: A total number of 193 hospitalized patients with COVID-19 were enrolled and analyzed. Median age was 61 years (95% CI: 58-64). Patients with baseline RDW ≥14.5% (n = 41, 19.2%) presented with more progressive disease compared to patients with baseline RDW <14.5% (n = 156, 80.8%) as indicated by significant differences in maximum FiO2% during hospitalization (median: 100, 95% CI: 45.2-100, vs. 35, 95% CI: 31-40, p = 0.0001, respectively). Values of RDW ≥14.5% were also strongly associated with increased risk of mortality (HR: 4.1, 95% CI: 0.88-19.23), (p = 0.02). Conclusion: Our study provides evidence to support reproducibility and validity of a specified cut-off threshold of RDW as biomarker of disease severity and mortality in patients with COVID-19.
Authors: Steven D Nathan; Taylor Reffett; A Whitney Brown; Chelsea P Fischer; Oksana A Shlobin; Shahzad Ahmad; Nargues Weir; Michael J Sheridan Journal: Chest Date: 2013-06 Impact factor: 9.410
Authors: Luca Spiezia; Annalisa Boscolo; Francesco Poletto; Lorenzo Cerruti; Ivo Tiberio; Elena Campello; Paolo Navalesi; Paolo Simioni Journal: Thromb Haemost Date: 2020-04-21 Impact factor: 5.249
Authors: Christoph C Kaufmann; Amro Ahmed; Ulrich Brunner; Bernhard Jäger; Gabriele Aicher; Susanne Equiluz-Bruck; Alexander O Spiel; Georg-Christian Funk; Michael Gschwantler; Peter Fasching; Kurt Huber Journal: Front Med (Lausanne) Date: 2021-03-18
Authors: Dennis Swearingen; Gregory Boverman; Kristen Tgavalekos; David P Noren; Shreyas Ravindranath; Erina Ghosh; Minnan Xu; Lisa Wondrely; Pam Thompson; J David Cowden; Corneliu Antonescu Journal: J Clin Med Date: 2021-10-08 Impact factor: 4.241